Navigation Links
New biomarker may predict leukemia aggressiveness
Date:4/19/2009

Scientists at the University of California, San Diego and the Moores UCSD Cancer Center have evidence of a potential new biomarker to predict the aggressiveness of an often difficult-to-treat form of leukemia. They found that high levels of a particular enzyme in the blood are an indicator that chronic lymphocytic leukemia (CLL) the most common form of adult leukemia will be aggressive and in need of immediate treatment.

The researchers, led by Paul A. Insel, MD, professor of pharmacology and medicine at the UC San Diego School of Medicine, say that the enzyme, PDE7B, is also critical to the development of CLL and a potential target for drugs against the disease. They present their results April 19, 2009 at the AACR 100th Annual Meeting 2009 in Denver.

One of the problems in deciding on the right therapy for CLL is that it is difficult to know which type of leukemia a patient has. One form progresses slowly, with few symptoms for years while the other form is more aggressive and dangerous. While tests exist and are commonly used to help doctors predict which form a patient may have, their availability and usefulness are limited.

In previous work, Insel's group had discovered that among a group of enzymes, cyclic nucleotide phosphodiesterases, one of the phosphodiesterases, PDE7B, was 10 times higher in CLL patients than in healthy individuals. PDE7B controls the levels of cyclic AMP (cAMP), a molecule that can promote programmed cell death, a process that is defective in CLL. Whereas most cancers have out-of-control cell growth, CLL is characterized by an overabundance of white blood cells that do not die when they should. High levels of PDE7B mean less cAMP and as a result, less cell death.

"The question was, could the level of PDE7B expression provide evidence for the clinical stage and diagnosis for individual patients?" Insel said. To find out if changes in PDE7B levels might reflect disease progression, Insel, postodoctoral fellow Linghzi Zhang, PhD, and their co-workers compared the amount of PDE7B in white blood cells in 85 untreated patients with CLL to those of 30 healthy adults, and watched for changes over time. They then divided the results into patients who had high levels of PDE7B and those who had low amounts.

"We found that individuals with high levels really had worse disease and showed that PDE7B expression had predictive value relative to other currently available markers for disease severity and progression," Insel said. "In some cases, the level of PDE7B expression provided prognostic information that was additive to existing markers."

Zhang said that PDE7B can be used alone as a biomarker for CLL if the levels are high enough, but may be used with other markers if the level is lower and ambiguous. "PDE7B may not be good enough by itself if it's not high enough," she noted. "If it is low, other markers could be helpful."

Co-investigator and leukemia expert Thomas Kipps, MD, PhD, professor of medicine and deputy director for research at the Moores UCSD Cancer Center, said that the findings are potentially important because of the urgency for clinicians to be able to gauge early on what kind of disease the CLL patient has in order to design the best available therapy.

Insel said that their research to date implies that PDE7B has a role in prognosis and could also be a good drug target because it reflects part of the biology of the disease. "The more of this enzyme a patient has, the worse the outcome," he said. "This implies that if we can develop drugs to block this enzyme, which would raise cAMP and promote apoptosis which is really at the heart of the underlying pathology."


'/>"/>

Contact: Steve Benowitz
sbenowitz@ucsd.edu
619-543-6163
University of California - San Diego
Source:Eurekalert

Related medicine news :

1. First biomarker discovered that predicts prostate cancer outcome
2. Penn School of Medicine receives $2.3 million to study biomarkers of cigarette smoke exposure
3. Study makes progress in zoning in on biomarkers for better colon cancer treatment
4. New Ovarian Cancer Biomarker Research Act Introduced
5. Mayo Clinic study points to a possible biomarker for colon cancer in people 50 and under
6. Singulex Announces Presentation on Monitoring of Cardiac Biomarker to Assess Transient Myocardial Ischemia at the American Heart Association Scientific Sessions
7. Biomarker may be an early predictor of advanced breast cancer
8. Millennium Announces MLN1202 Significantly Reduced Marker of Systemic Inflammation and Identifies Genomic Biomarker For Responders
9. Biomarkers predict risk for invasive breast cancer years before the tumor develops
10. JDRF and Lilly partner to fund research to identify beta cell biomarkers
11. Biomarkers for Alzheimers disease can be trusted in clinical trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... ... September 20, 2017 , ... ... specializing in medical device compliance and commercialization, has just released a new ... , FDA is more adamant than ever about medical device, pharmaceutical, and ...
(Date:9/20/2017)... ... September 20, 2017 , ... As part of The Garland ... a redesigned website. The new site – still located at http://www.garlandco.com ... and other industry users that Garland serves. , After an ambitious phase of ...
(Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... ... digital and social campaign, “Humans With Vaginas.” The goal is to ignite conversation ... of non-toxic personal care products. The brand has declared September “Humans with Vaginas” ...
(Date:9/20/2017)... ... 20, 2017 , ... Health & Safety Institute (HSI) is offering discounted pricing ... 40-Hour courses from now until November 30, 2017 to assist with the clean-up efforts ... to all businesses and government agencies – whether or not they will be directly ...
(Date:9/20/2017)... ... September 20, 2017 , ... “Finn Mouseson”: follows the exciting story of ... life. This mouse sets out on a journey that will show that friends are ... creation of newly published author and illustrator, Melody Gersonde-Mickelson, who has earned a bachelor’s ...
Breaking Medicine News(10 mins):
(Date:9/12/2017)... 12, 2017  ValGenesis Inc., the global leader ... pleased to announce the appointment of Dr. ... Board of Directors and Chairman of Advisory Board ... science companies to manage their entire validation lifecycle ... in this process. Furthermore, ValGenesis VLMS enables rigorous ...
(Date:9/9/2017)... -- Eli Lilly and Company (NYSE: LLY ) ... lasmiditan, an investigational, oral, first-in-class molecule for the acute ... to placebo in the Phase 3 SPARTAN study. Detailed ... of the International Headache Society (IHC) in ... demonstrate lasmiditan,s potential to reduce pain and provide freedom ...
(Date:9/7/2017)... , Sept. 7, 2017 Caris Life ... on fulfilling the promise of precision medicine, today ... the benefits of its molecular profiling approach in ... comprehensive genomic profiling plus (CGP+) with Caris Molecular ... tumor on a molecular level, leading to more ...
Breaking Medicine Technology: